Income Statement Finch Therapeutics Group, Inc.
Stocks
FNCH.Q
US31773D2009
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
15:12:40 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 10.35 USD | -1.43% |
|
0.00% | -23.26% |
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Revenues | 10.15M | 7.72M | 18.53M | 861K | 107K |
Total Revenues | 10.15M | 7.72M | 18.53M | 861K | 107K |
Cost of Goods Sold, Total | 23.86M | 33.14M | 57.28M | 57.89M | 7.2M |
Gross Profit | -13.7M | -25.42M | -38.75M | -57.03M | -7.09M |
Selling General & Admin Expenses, Total | 7.44M | 14.01M | 21.24M | 38.09M | 26.91M |
Other Operating Expenses, Total | 7.44M | 14.01M | 21.24M | 38.09M | 26.91M |
Operating Income | -21.14M | -39.44M | -59.98M | -95.12M | -34M |
Interest And Investment Income | 488K | 106K | 22K | 252K | 1.57M |
Net Interest Expenses | 488K | 106K | 22K | 252K | 1.57M |
Currency Exchange Gains (Loss) | - | - | -52K | - | - |
Other Non Operating Income (Expenses) | - | 2K | - | 702K | 4.05M |
EBT, Excl. Unusual Items | -20.65M | -39.33M | -60.02M | -94.17M | -28.38M |
Restructuring Charges | - | - | - | -2.42M | -3.82M |
Impairment of Goodwill | - | - | - | -18.06M | - |
Gain (Loss) On Sale Of Assets | -140K | -13K | 28K | -7K | 637K |
Asset Writedown | - | - | - | - | -13.14M |
In Process R&D Expenses | - | - | - | - | -32.9M |
Insurance Settlements | 40K | - | - | - | - |
Other Unusual Items | - | - | 1.83M | - | -614K |
EBT, Incl. Unusual Items | -20.75M | -39.34M | -58.16M | -115M | -78.22M |
Income Tax Expense | - | - | - | - | -3.46M |
Earnings From Continuing Operations | -20.75M | -39.34M | -58.16M | -115M | -74.75M |
Net Income to Company | -20.75M | -39.34M | -58.16M | -115M | -74.75M |
Net Income - (IS) | -20.75M | -39.34M | -58.16M | -115M | -74.75M |
Net Income to Common Incl Extra Items | -20.75M | -39.34M | -58.16M | -115M | -74.75M |
Net Income to Common Excl. Extra Items | -20.75M | -39.34M | -58.16M | -115M | -74.75M |
Per Share Items | |||||
Net EPS - Basic | -85.34 | -144.91 | -44.51 | -72.12 | -46.59 |
Basic EPS - Continuing Operations | -85.34 | -144.91 | -44.51 | -72.12 | -46.59 |
Basic Weighted Average Shares Outstanding | 243K | 271K | 1.31M | 1.59M | 1.6M |
Net EPS - Diluted | -85.34 | -144.91 | -44.51 | -72.12 | -46.59 |
Diluted EPS - Continuing Operations | -85.34 | -144.91 | -44.51 | -72.12 | -46.59 |
Diluted Weighted Average Shares Outstanding | 243K | 271K | 1.31M | 1.59M | 1.6M |
Normalized Basic EPS | -53.08 | -90.54 | -28.7 | -37.02 | -11.05 |
Normalized Diluted EPS | -53.08 | -90.54 | -28.7 | -37.02 | -11.05 |
Supplemental Items | |||||
EBITDA | -20.66M | -38.65M | -57.68M | -89.61M | -32.48M |
EBITA | -21.14M | -39.44M | -59.98M | -95.12M | -34M |
EBIT | -21.14M | -39.44M | -59.98M | -95.12M | -34M |
EBITDAR | -19.43M | -39.05M | -55.66M | -82.96M | -30.59M |
Total Revenues (As Reported) | 10.15M | 7.72M | 18.53M | 861K | 107K |
Effective Tax Rate - (Ratio) | - | - | - | - | 4.42 |
Total Deferred Taxes | - | - | - | - | -3.46M |
Normalized Net Income | -12.91M | -24.58M | -37.51M | -58.85M | -17.74M |
Interest on Long-Term Debt | - | - | 10K | 4K | - |
Supplemental Operating Expense Items | |||||
General and Administrative Expenses | 7.44M | 14.01M | 21.24M | 38.09M | 26.91M |
Research And Development Expense From Footnotes | 23.54M | 33.14M | 57.28M | 57.89M | 7.2M |
Net Rental Expense, Total | 1.23M | -400K | 2.03M | 6.65M | 1.89M |
Stock-Based Comp., COGS (Total) | 389K | 179K | 1.6M | 3.26M | 231K |
Stock-Based Comp., G&A Exp. (Total) | 217K | 2.92M | 2.56M | 4.58M | 1.7M |
Total Stock-Based Compensation | 606K | 3.1M | 4.16M | 7.84M | 1.93M |
- Stock Market
- Stocks
- FNCH.Q Stock
- Financials Finch Therapeutics Group, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
